Surgical & medical instruments Stocks List

This page shows information about the 50 largest surgical & medical instruments industry stocks including Boston Scientific, Stryker, 3M, and Becton, Dickinson and Company.

1. Boston Scientific NYSE:BSX

$96.70 +1.19 (+1.24%)

As of 03:16 PM Eastern

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

The stock price recently reached $104.02, reflecting a 3.2% increase, indicating positive market sentiment and potential for further growth.
Boston Scientific Co. reported earnings per share (EPS) of $0.70, surpassing analysts' expectations of $0.65, which demonstrates strong financial performance and effective management.
Insider trading activity shows confidence in the company, with executives recently selling shares, which can indicate a strategic repositioning rather than a lack of confidence in the company's future.

Cons of Boston Scientific

The company's price-to-earnings (P/E) ratio is 83.21, which is significantly higher than the industry average, indicating that the stock may be overvalued and could face corrections.
Insiders have sold a total of 144,305 shares valued at nearly $15 million over the last quarter, which could raise concerns about their confidence in the company's future performance.
Despite recent growth, the company has a relatively low net margin of 11.07%, which may limit its profitability compared to competitors in the medical device industry.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $142.77 billion
P/E Ratio: 77.39
Consensus Rating: Buy
Consensus Price Target: $108.91 (+12.6% Upside)
Volume: 4.95 million shares
Average Volume: 5.76 million shares
Today's Range: $96.01
▼
$98.57
50-Day Range: $89.32
▼
$106.20
52-Week Range: $65.52
▼
$107.17
Dividend Yield: N/A

2. Stryker NYSE:SYK

$364.74 -0.55 (-0.15%)

As of 03:16 PM Eastern

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

Stryker Co. recently reported earnings per share of $4.01, exceeding analysts' expectations of $3.87, indicating strong financial performance and potential for growth.
The stock has a market capitalization of approximately $144.73 billion, reflecting its significant presence in the medical technology sector and stability as a large-cap stock.
With a current stock price around $381.86, it is trading near its fifty-two week high of $406.19, suggesting positive market sentiment and potential for further appreciation.

Cons of Stryker

The stock has a high P/E ratio of 48.88, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
Recent insider selling, including a significant transaction by Director Ronda E. Stryker, may raise concerns about the company's future prospects and insider confidence.
Analysts have mixed ratings, with some downgrading the stock from "buy" to "hold," suggesting uncertainty about its short-term performance.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $139.20 billion
P/E Ratio: 47.01
Consensus Rating: Moderate Buy
Consensus Price Target: $421.90 (+15.7% Upside)
Volume: 1.05 million shares
Average Volume: 1.21 million shares
Today's Range: $361.34
▼
$371.11
50-Day Range: $355.17
▼
$399.83
52-Week Range: $314.93
▼
$406.19
Dividend Yield: 0.88%

3. 3M NYSE:MMM

$150.64 +3.10 (+2.10%)

As of 03:16 PM Eastern

3M Company provides diversified technology services in the United States and internationally. The company's Safety and Industrial segment offers industrial abrasives and finishing for metalworking applications; autobody repair solutions; closure systems for personal hygiene products, masking, and packaging materials; electrical products and materials for construction and maintenance, power distribution, and electrical original equipment manufacturers; structural adhesives and tapes; respiratory, hearing, eye, and fall protection solutions; and natural and color-coated mineral granules for shingles. Its Transportation and Electronics segment provides ceramic solutions; attachment/bonding products, films, sound, and temperature management for transportation vehicles; premium large format graphic films for advertising and fleet signage; light management films and electronics assembly solutions; packaging and interconnection solutions; semiconductor production materials; data centers solutions; and reflective signage for highway, and vehicle safety. The company's Consumer segment provides consumer bandages, braces, supports, and consumer respirators; home cleaning products; retail abrasives, paint accessories, car care DIY products, picture hanging, and consumer air quality solutions; and stationery products. It offers its products through e-commerce and traditional wholesalers, retailers, jobbers, distributors, and dealers. 3M Company was founded in 1902 and is headquartered in Saint Paul, Minnesota.

Market Capitalization: $81.89 billion
P/E Ratio: 19.98
Consensus Rating: Moderate Buy
Consensus Price Target: $149.13 (-1.0% Downside)
Volume: 2.59 million shares
Average Volume: 4.32 million shares
Today's Range: $147.20
▼
$151.24
50-Day Range: $129.09
▼
$155.25
52-Week Range: $81.23
▼
$156.35
Dividend Yield: 2.00%

4. Becton, Dickinson and Company NYSE:BDX

$224.24 -0.68 (-0.30%)

As of 03:16 PM Eastern

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

Becton, Dickinson and Company reported earnings per share of $3.43, exceeding analysts' expectations of $3.00 by $0.43, indicating strong financial performance and effective management.
The company has a consensus rating of "Buy" from eight investment analysts, suggesting positive sentiment and confidence in its future performance.
Barclays and Piper Sandler have recently raised their price targets for Becton, Dickinson and Company to $279.00 and $280.00 respectively, reflecting optimism about the company's growth potential.

Cons of Becton, Dickinson and Company

The company's net margin is 8.47%, which may indicate lower profitability compared to competitors, potentially affecting long-term growth prospects.
Insider transactions show that executives have sold a total of 5,423 shares worth $1,239,780 in the last 90 days, which could signal a lack of confidence in the company's short-term performance.
The payout ratio is 69.10%, suggesting that a significant portion of earnings is being distributed as dividends, which may limit funds available for reinvestment in growth opportunities.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $64.36 billion
P/E Ratio: 37.23
Consensus Rating: Buy
Consensus Price Target: $278.29 (+24.1% Upside)
Volume: 1.36 million shares
Average Volume: 1.51 million shares
Today's Range: $223.51
▼
$227.31
50-Day Range: $224.17
▼
$249.75
52-Week Range: $218.75
▼
$251.99
Dividend Yield: 1.81%

5. ResMed NYSE:RMD

$221.19 -4.60 (-2.04%)

As of 03:16 PM Eastern

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More about ResMed

Pros of ResMed

ResMed Inc. has a strong earnings forecast, with analysts expecting an EPS of 9.47 for the current fiscal year, indicating potential for growth and profitability.
The company recently reported a quarterly earnings per share of $2.43, surpassing analysts' expectations, which reflects its strong operational performance.
ResMed Inc. has declared a quarterly dividend of $0.53 per share, translating to an annualized dividend of $2.12 and a yield of 0.91%, providing a return on investment for shareholders.

Cons of ResMed

Recent analyst downgrades, including a shift from a "buy" to a "hold" rating, may indicate concerns about the stock's future performance and market sentiment.
The company has a relatively low dividend payout ratio of 25.03%, which may suggest limited returns for income-focused investors compared to other options in the market.
Insider selling activity, with significant shares sold recently, could raise red flags about the company's future prospects and insider confidence.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $32.49 billion
P/E Ratio: 26.12
Consensus Rating: Moderate Buy
Consensus Price Target: $243.82 (+10.2% Upside)
Volume: 389,866 shares
Average Volume: 970,717 shares
Today's Range: $217.67
▼
$222.94
50-Day Range: $223.76
▼
$257.63
52-Week Range: $172.19
▼
$263.05
Dividend Yield: 0.91%

Remove Ads

6. DexCom NASDAQ:DXCM

$70.77 +0.51 (+0.72%)

As of 03:16 PM Eastern

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. More about DexCom

Pros of DexCom

Recent upgrades from analysts, including a price target increase to $104.00, indicate strong market confidence in DexCom, Inc.'s growth potential.
The company reported a return on equity of 30.14%, showcasing its ability to generate profit from shareholders' equity, which is a positive indicator for investors.
DexCom, Inc. has a consensus rating of "Moderate Buy" from analysts, with 13 buy ratings and only 4 hold ratings, suggesting strong market support.

Cons of DexCom

The company missed analysts' consensus estimates for earnings per share (EPS) by $0.05, which may raise concerns about its short-term profitability.
Recent insider selling, including significant sales by the CEO and other executives, could signal a lack of confidence in the company's near-term performance.
Despite a strong market position, the stock has experienced volatility, with a one-year low of $62.34, which may deter risk-averse investors.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $27.67 billion
P/E Ratio: 49.51
Consensus Rating: Moderate Buy
Consensus Price Target: $99.82 (+41.1% Upside)
Volume: 3.42 million shares
Average Volume: 3.86 million shares
Today's Range: $69.86
▼
$72.30
50-Day Range: $70.26
▼
$90.75
52-Week Range: $62.34
▼
$142.00
Dividend Yield: N/A

7. Baxter International NYSE:BAX

$34.38 -1.47 (-4.11%)

As of 03:16 PM Eastern

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. More about Baxter International

Pros of Baxter International

Baxter International Inc. recently reported earnings per share of $0.58, exceeding analysts' expectations of $0.52, indicating strong financial performance and potential for growth.
The company has a positive return on equity of 16.67%, suggesting effective management and profitability relative to shareholder equity.
With a current stock price of $35.07, Baxter International Inc. is trading below some analysts' price targets, which may indicate potential for price appreciation.

Cons of Baxter International

The stock has a negative net margin of 5.05%, indicating that the company is currently not profitable on a net income basis, which could be a concern for investors.
Analysts have mixed ratings, with one sell rating and several hold ratings, suggesting uncertainty about the stock's future performance.
The company has a high debt-to-equity ratio of 1.31, which may indicate higher financial risk and potential challenges in managing debt obligations.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $17.59 billion
P/E Ratio: -26.86
Consensus Rating: Hold
Consensus Price Target: $38.56 (+12.2% Upside)
Volume: 3.61 million shares
Average Volume: 4.23 million shares
Today's Range: $34.21
▼
$35.77
50-Day Range: $29.16
▼
$36.64
52-Week Range: $28.34
▼
$43.99
Dividend Yield: 1.86%

8. Insulet NASDAQ:PODD

$248.70 +3.35 (+1.36%)

As of 03:16 PM Eastern

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Market Capitalization: $17.46 billion
P/E Ratio: 42.93
Consensus Rating: Moderate Buy
Consensus Price Target: $292.06 (+17.4% Upside)
Volume: 718,517 shares
Average Volume: 688,988 shares
Today's Range: $247.19
▼
$255.63
50-Day Range: $237.06
▼
$288.29
52-Week Range: $160.19
▼
$289.46
Dividend Yield: N/A

9. West Pharmaceutical Services NYSE:WST

$226.08 -4.70 (-2.03%)

As of 03:16 PM Eastern

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. More about West Pharmaceutical Services

Pros of West Pharmaceutical Services

The company recently reported earnings per share of $1.82, exceeding analysts' expectations of $1.75, indicating strong financial performance and effective management.
West Pharmaceutical Services, Inc. has a solid market capitalization of approximately $14.73 billion, reflecting its stability and growth potential in the medical instruments sector.
With a current stock price of $230.56, the shares have shown resilience, trading above their fifty-two week low of $197.01, suggesting investor confidence.

Cons of West Pharmaceutical Services

The stock has a relatively high P/E ratio of 30.41, which may suggest that it is overvalued compared to its earnings, potentially limiting future price appreciation.
Recent downgrades from analysts, including a shift from a "buy" to a "hold" rating, may indicate concerns about the stock's short-term performance and market sentiment.
The PEG ratio of 10.09 suggests that the stock may be expensive relative to its expected earnings growth, which could deter value-focused investors.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $16.34 billion
P/E Ratio: 33.79
Consensus Rating: Moderate Buy
Consensus Price Target: $344.00 (+52.2% Upside)
Volume: 508,176 shares
Average Volume: 971,666 shares
Today's Range: $221.94
▼
$230.74
50-Day Range: $199.40
▼
$347.51
52-Week Range: $197.01
▼
$400.88
Dividend Yield: 0.36%

10. Solventum NYSE:SOLV

$73.74 -2.15 (-2.83%)

As of 03:16 PM Eastern

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.

Market Capitalization: $12.76 billion
P/E Ratio: 26.82
Consensus Rating: Hold
Consensus Price Target: $79.86 (+8.3% Upside)
Volume: 583,708 shares
Average Volume: 1.44 million shares
Today's Range: $73.73
▼
$76.18
50-Day Range: $65.93
▼
$83.83
52-Week Range: $47.16
▼
$85.92
Dividend Yield: N/A

Remove Ads

11. Penumbra NYSE:PEN

$265.98 +3.64 (+1.39%)

As of 03:16 PM Eastern

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Market Capitalization: $10.25 billion
P/E Ratio: 782.51
Consensus Rating: Moderate Buy
Consensus Price Target: $292.64 (+10.0% Upside)
Volume: 199,736 shares
Average Volume: 396,507 shares
Today's Range: $264.70
▼
$272.72
50-Day Range: $236.12
▼
$303.55
52-Week Range: $148.00
▼
$310.00
Dividend Yield: N/A

12. Globus Medical NYSE:GMED

$71.00 -2.49 (-3.39%)

As of 03:16 PM Eastern

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Market Capitalization: $9.76 billion
P/E Ratio: 94.64
Consensus Rating: Moderate Buy
Consensus Price Target: $97.82 (+37.8% Upside)
Volume: 1.54 million shares
Average Volume: 1.31 million shares
Today's Range: $70.59
▼
$74.73
50-Day Range: $73.39
▼
$93.25
52-Week Range: $49.33
▼
$94.93
Dividend Yield: N/A

13. Teleflex NYSE:TFX

$134.96 -3.86 (-2.78%)

As of 03:16 PM Eastern

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

Market Capitalization: $6.26 billion
P/E Ratio: 26.85
Consensus Rating: Hold
Consensus Price Target: $182.63 (+35.3% Upside)
Volume: 585,579 shares
Average Volume: 848,586 shares
Today's Range: $134.68
▼
$139.02
50-Day Range: $130.87
▼
$183.81
52-Week Range: $128.55
▼
$249.90
Dividend Yield: 1.00%

14. Stevanato Group NYSE:STVN

€20.16 -0.98 (-4.64%)

As of 02:59 PM Eastern

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

Market Capitalization: $6.11 billion
P/E Ratio: 42.89
Consensus Rating: Moderate Buy
Consensus Price Target: N/A
Volume: 303,126 shares
Average Volume: 348,788 shares
Today's Range: €19.67
▼
€21.40
50-Day Range: €17.90
▼
€24.04
52-Week Range: €16.56
▼
€33.49
Dividend Yield: 0.27%

15. Glaukos NYSE:GKOS

$102.38 +4.59 (+4.69%)

As of 03:16 PM Eastern

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Market Capitalization: $5.79 billion
P/E Ratio: -35.63
Consensus Rating: Moderate Buy
Consensus Price Target: $163.25 (+59.5% Upside)
Volume: 781,370 shares
Average Volume: 839,560 shares
Today's Range: $99.73
▼
$103.27
50-Day Range: $96.32
▼
$161.55
52-Week Range: $84.08
▼
$163.71
Dividend Yield: N/A

Remove Ads

16. Merit Medical Systems NASDAQ:MMSI

$97.95 -0.45 (-0.46%)

As of 03:16 PM Eastern

Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. It also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate structures; gastroenterology products, such as covered esophageal stents, syringe and gauges, and balloon dilators; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.

Market Capitalization: $5.77 billion
P/E Ratio: 48.04
Consensus Rating: Buy
Consensus Price Target: $110.78 (+13.1% Upside)
Volume: 143,019 shares
Average Volume: 580,594 shares
Today's Range: $96.54
▼
$99.33
50-Day Range: $95.64
▼
$110.29
52-Week Range: $70.70
▼
$111.45
Dividend Yield: N/A

17. Inspire Medical Systems NYSE:INSP

$163.66 -9.16 (-5.30%)

As of 03:16 PM Eastern

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.

Market Capitalization: $4.86 billion
P/E Ratio: 94.62
Consensus Rating: Moderate Buy
Consensus Price Target: $228.82 (+39.8% Upside)
Volume: 387,817 shares
Average Volume: 578,096 shares
Today's Range: $163.30
▼
$176.45
50-Day Range: $169.71
▼
$214.98
52-Week Range: $123.00
▼
$257.40
Dividend Yield: N/A

18. Inari Medical NASDAQ:NARI

$79.97 0.00 (0.00%)

As of 02/19/2025

Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

Market Capitalization: $4.68 billion
P/E Ratio: -59.24
Consensus Rating: Hold
Consensus Price Target: $68.00 (-15.0% Downside)
Volume: N/A
Average Volume: 986,853 shares
Today's Range: $79.97
▼
$79.97
50-Day Range: $49.77
▼
$79.97
52-Week Range: $36.73
▼
$79.99
Dividend Yield: N/A

19. ICU Medical NASDAQ:ICUI

$141.57 +2.58 (+1.86%)

As of 03:16 PM Eastern

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.

Market Capitalization: $3.47 billion
P/E Ratio: -31.00
Consensus Rating: Buy
Consensus Price Target: $168.67 (+19.1% Upside)
Volume: 175,877 shares
Average Volume: 230,062 shares
Today's Range: $139.86
▼
$145.00
50-Day Range: $130.05
▼
$172.30
52-Week Range: $93.36
▼
$196.26
Dividend Yield: N/A

20. Haemonetics NYSE:HAE

$65.93 -2.37 (-3.47%)

As of 03:16 PM Eastern

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Market Capitalization: $3.31 billion
P/E Ratio: 25.98
Consensus Rating: Moderate Buy
Consensus Price Target: $101.67 (+54.2% Upside)
Volume: 471,670 shares
Average Volume: 1.00 million shares
Today's Range: $65.07
▼
$68.38
50-Day Range: $59.34
▼
$80.05
52-Week Range: $58.80
▼
$97.97
Dividend Yield: N/A

Remove Ads

21. iRhythm Technologies NASDAQ:IRTC

$102.96 -0.95 (-0.92%)

As of 03:16 PM Eastern

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

Market Capitalization: $3.23 billion
P/E Ratio: -28.22
Consensus Rating: Moderate Buy
Consensus Price Target: $119.73 (+16.3% Upside)
Volume: 203,777 shares
Average Volume: 470,561 shares
Today's Range: $102.16
▼
$106.00
50-Day Range: $89.44
▼
$119.58
52-Week Range: $55.92
▼
$128.52
Dividend Yield: N/A

22. PROCEPT BioRobotics NASDAQ:PRCT

$58.24 -1.33 (-2.23%)

As of 03:16 PM Eastern

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

Market Capitalization: $3.19 billion
P/E Ratio: -29.86
Consensus Rating: Moderate Buy
Consensus Price Target: $94.29 (+61.9% Upside)
Volume: 503,355 shares
Average Volume: 717,194 shares
Today's Range: $57.00
▼
$62.90
50-Day Range: $57.59
▼
$88.57
52-Week Range: $45.56
▼
$103.81
Dividend Yield: N/A

23. NovoCure NASDAQ:NVCR

$20.75 -0.57 (-2.67%)

As of 03:16 PM Eastern

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Market Capitalization: $2.28 billion
P/E Ratio: -14.81
Consensus Rating: Moderate Buy
Consensus Price Target: $32.67 (+57.4% Upside)
Volume: 738,003 shares
Average Volume: 1.25 million shares
Today's Range: $20.35
▼
$21.55
50-Day Range: $18.19
▼
$30.19
52-Week Range: $11.70
▼
$34.13
Dividend Yield: N/A

24. LeMaitre Vascular NASDAQ:LMAT

$81.86 -0.44 (-0.53%)

As of 03:16 PM Eastern

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

Market Capitalization: $1.85 billion
P/E Ratio: 44.79
Consensus Rating: Moderate Buy
Consensus Price Target: $95.25 (+16.4% Upside)
Volume: 117,041 shares
Average Volume: 142,237 shares
Today's Range: $80.93
▼
$84.46
50-Day Range: $81.37
▼
$104.00
52-Week Range: $62.39
▼
$109.58
Dividend Yield: 0.79%

25. Integra LifeSciences NASDAQ:IART

$22.22 -1.74 (-7.24%)

As of 03:16 PM Eastern

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

Market Capitalization: $1.71 billion
P/E Ratio: -246.45
Consensus Rating: Reduce
Consensus Price Target: $23.00 (+3.5% Upside)
Volume: 511,426 shares
Average Volume: 1.01 million shares
Today's Range: $22.14
▼
$24.37
50-Day Range: $21.13
▼
$26.55
52-Week Range: $16.81
▼
$36.49
Dividend Yield: N/A

Remove Ads

26. UFP Technologies NASDAQ:UFPT

$210.59 -3.88 (-1.81%)

As of 03:16 PM Eastern

UFP Technologies, Inc. designs and manufactures solutions for medical devices, sterile packaging, and other highly engineered custom products. The company offers protective drapes for robotic surgery, single patient use surfaces, advanced wound care, infection prevention, disposables for surgical and endoscopic procedures, packaging for medical devices, orthopedic implants, biopharma drug manufacturing, and coils for catheters; and molded components for applications in acoustic insulation, interior trim, load floors, sunshades, SUV cargo cover handles, driveshaft damping, engine and manifold covers, quarter panels, and wheel liners. It also provides molded composites for commercial aviation and military gear for use in backpack components, knee and elbow pads, eyewear, and helmets; and reusable cases and custom for applications in military ballistics panels, virtual training systems, drones, communications equipment, and rugged portable computers. In addition, the company provides engineered products and components to customers in the automotive, aerospace and defense, and industrial markets for applications in military uniform and gear components, automotive interior trim, air filtration, and protective cases and inserts. It markets and sells its products through a direct sales force. The company was founded in 1963 and is headquartered in Newburyport, Massachusetts.

Market Capitalization: $1.62 billion
P/E Ratio: 30.05
Consensus Rating: Buy
Consensus Price Target: $323.50 (+53.6% Upside)
Volume: 77,234 shares
Average Volume: 108,715 shares
Today's Range: $206.36
▼
$215.00
50-Day Range: $212.88
▼
$285.04
52-Week Range: $188.50
▼
$366.41
Dividend Yield: N/A

27. AtriCure NASDAQ:ATRC

$33.06 -0.88 (-2.58%)

As of 03:16 PM Eastern

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Market Capitalization: $1.62 billion
P/E Ratio: -34.83
Consensus Rating: Buy
Consensus Price Target: $51.56 (+55.9% Upside)
Volume: 400,344 shares
Average Volume: 664,551 shares
Today's Range: $32.84
▼
$34.54
50-Day Range: $30.40
▼
$42.40
52-Week Range: $18.94
▼
$43.11
Dividend Yield: N/A

28. Alphatec NASDAQ:ATEC

$9.66 -0.29 (-2.86%)

As of 03:16 PM Eastern

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

Market Capitalization: $1.39 billion
P/E Ratio: -7.53
Consensus Rating: Moderate Buy
Consensus Price Target: $17.67 (+82.8% Upside)
Volume: 866,639 shares
Average Volume: 1.98 million shares
Today's Range: $9.61
▼
$10.05
50-Day Range: $9.06
▼
$12.53
52-Week Range: $4.88
▼
$14.88
Dividend Yield: N/A

29. Tandem Diabetes Care NASDAQ:TNDM

$18.69 +0.80 (+4.47%)

As of 03:16 PM Eastern

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Market Capitalization: $1.24 billion
P/E Ratio: -9.69
Consensus Rating: Moderate Buy
Consensus Price Target: $45.38 (+142.8% Upside)
Volume: 1.32 million shares
Average Volume: 1.47 million shares
Today's Range: $18.03
▼
$19.34
50-Day Range: $17.89
▼
$37.53
52-Week Range: $17.64
▼
$53.69
Dividend Yield: N/A

30. MiMedx Group NASDAQ:MDXG

$8.09 -0.04 (-0.43%)

As of 03:16 PM Eastern

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Market Capitalization: $1.19 billion
P/E Ratio: 14.71
Consensus Rating: Buy
Consensus Price Target: $12.00 (+48.4% Upside)
Volume: 305,810 shares
Average Volume: 708,746 shares
Today's Range: $7.88
▼
$8.20
50-Day Range: $7.79
▼
$9.62
52-Week Range: $5.47
▼
$10.14
Dividend Yield: N/A

Remove Ads

31. Paragon 28 NYSE:FNA

$13.06 +0.06 (+0.42%)

As of 03:16 PM Eastern

Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; and total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides forefoot or hallux valgus correction systems, including phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.

Market Capitalization: $1.09 billion
P/E Ratio: -17.66
Consensus Rating: Hold
Consensus Price Target: $14.20 (+8.7% Upside)
Volume: 1.21 million shares
Average Volume: 842,659 shares
Today's Range: $13.06
▼
$13.08
50-Day Range: $10.29
▼
$13.09
52-Week Range: $4.65
▼
$13.13
Dividend Yield: N/A

32. Pulse Biosciences NASDAQ:PLSE

$17.46 +0.32 (+1.87%)

As of 03:16 PM Eastern

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

Market Capitalization: $1.07 billion
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 76,747 shares
Average Volume: 151,660 shares
Today's Range: $17.21
▼
$17.91
50-Day Range: $16.92
▼
$24.56
52-Week Range: $6.59
▼
$25.00
Dividend Yield: N/A

33. Artivion NYSE:AORT

$23.68 +0.20 (+0.83%)

As of 03:16 PM Eastern

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Market Capitalization: $996.75 million
P/E Ratio: -1,185.25
Consensus Rating: Buy
Consensus Price Target: $31.40 (+32.6% Upside)
Volume: 188,882 shares
Average Volume: 258,006 shares
Today's Range: $23.26
▼
$23.84
50-Day Range: $23.48
▼
$31.69
52-Week Range: $19.11
▼
$32.33
Dividend Yield: N/A

34. Bioventus NYSE:BVS

$10.10 -0.71 (-6.53%)

As of 03:16 PM Eastern

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Market Capitalization: $819.34 million
P/E Ratio: -16.55
Consensus Rating: Moderate Buy
Consensus Price Target: $15.00 (+48.6% Upside)
Volume: 719,184 shares
Average Volume: 420,052 shares
Today's Range: $9.77
▼
$10.84
50-Day Range: $8.76
▼
$11.05
52-Week Range: $3.90
▼
$14.38
Dividend Yield: N/A

35. Embecta NASDAQ:EMBC

$13.38 -0.95 (-6.60%)

As of 03:16 PM Eastern

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

Market Capitalization: $779.11 million
P/E Ratio: 13.40
Consensus Rating: Moderate Buy
Consensus Price Target: $23.00 (+72.0% Upside)
Volume: 646,604 shares
Average Volume: 415,037 shares
Today's Range: $13.37
▼
$14.35
50-Day Range: $12.60
▼
$20.93
52-Week Range: $9.93
▼
$21.48
Dividend Yield: 4.71%

Remove Ads

36. Iradimed NASDAQ:IRMD

$52.46 +0.15 (+0.29%)

As of 03:16 PM Eastern

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

Market Capitalization: $666.09 million
P/E Ratio: 35.04
Consensus Rating: Buy
Consensus Price Target: $72.00 (+37.2% Upside)
Volume: 39,897 shares
Average Volume: 40,914 shares
Today's Range: $51.26
▼
$53.21
50-Day Range: $51.98
▼
$62.67
52-Week Range: $40.18
▼
$63.29
Dividend Yield: 1.30%

37. Orthofix Medical NASDAQ:OFIX

$16.76 -0.34 (-1.97%)

As of 03:16 PM Eastern

Orthofix Medical Inc. operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations. The Global Orthopedics segment offers products and solutions that allow physicians to treat various orthopedic conditions related to limb reconstruction and deformity correction unrelated to the spine. This segment designs, develops, and markets external and internal fixation orthopedic products that are coupled with enabling digital technologies to serve the complete patient treatment pathway. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.

Market Capitalization: $654.20 million
P/E Ratio: -5.36
Consensus Rating: Moderate Buy
Consensus Price Target: $23.33 (+39.2% Upside)
Volume: 67,917 shares
Average Volume: 193,340 shares
Today's Range: $16.53
▼
$17.28
50-Day Range: $16.74
▼
$19.04
52-Week Range: $12.08
▼
$20.73
Dividend Yield: N/A

38. SI-BONE NASDAQ:SIBN

$14.83 -0.55 (-3.59%)

As of 03:16 PM Eastern

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

Market Capitalization: $631.32 million
P/E Ratio: -16.16
Consensus Rating: Buy
Consensus Price Target: $24.50 (+65.2% Upside)
Volume: 226,905 shares
Average Volume: 357,955 shares
Today's Range: $14.87
▼
$15.64
50-Day Range: $13.72
▼
$18.44
52-Week Range: $11.70
▼
$19.16
Dividend Yield: N/A

39. Beta Bionics NASDAQ:BBNX

$14.61 -0.41 (-2.73%)

As of 02:55 PM Eastern

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

Market Capitalization: $626.17 million
P/E Ratio: N/A
Consensus Rating: Moderate Buy
Consensus Price Target: $24.83 (+70.0% Upside)
Volume: 204,324 shares
Average Volume: 369,100 shares
Today's Range: $14.59
▼
$15.63
50-Day Range: $0.00
▼
$0.00
52-Week Range: $13.64
▼
$24.50
Dividend Yield: N/A

40. OrthoPediatrics NASDAQ:KIDS

$25.15 -0.57 (-2.22%)

As of 03:16 PM Eastern

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

Market Capitalization: $611.33 million
P/E Ratio: -20.46
Consensus Rating: Moderate Buy
Consensus Price Target: $37.25 (+48.1% Upside)
Volume: 89,673 shares
Average Volume: 311,112 shares
Today's Range: $24.78
▼
$26.02
50-Day Range: $22.87
▼
$27.24
52-Week Range: $21.02
▼
$35.99
Dividend Yield: N/A

Remove Ads

41. Treace Medical Concepts NASDAQ:TMCI

$8.24 -0.06 (-0.66%)

As of 03:16 PM Eastern

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

Market Capitalization: $514.92 million
P/E Ratio: -8.31
Consensus Rating: Hold
Consensus Price Target: $10.21 (+24.0% Upside)
Volume: 153,346 shares
Average Volume: 728,718 shares
Today's Range: $8.17
▼
$8.71
50-Day Range: $7.30
▼
$10.54
52-Week Range: $3.92
▼
$13.24
Dividend Yield: N/A

42. Delcath Systems NASDAQ:DCTH

$12.10 +0.30 (+2.50%)

As of 03:16 PM Eastern

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Market Capitalization: $386.92 million
P/E Ratio: -8.96
Consensus Rating: Buy
Consensus Price Target: $22.75 (+88.1% Upside)
Volume: 160,213 shares
Average Volume: 330,216 shares
Today's Range: $11.66
▼
$12.54
50-Day Range: $11.48
▼
$16.45
52-Week Range: $3.70
▼
$16.97
Dividend Yield: N/A

43. Surmodics NASDAQ:SRDX

$26.78 -0.73 (-2.64%)

As of 03:16 PM Eastern

Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

Market Capitalization: $382.92 million
P/E Ratio: -26.52
Consensus Rating: Hold
Consensus Price Target: $50.00 (+86.7% Upside)
Volume: 117,349 shares
Average Volume: 309,536 shares
Today's Range: $26.59
▼
$27.79
50-Day Range: $27.51
▼
$39.71
52-Week Range: $25.17
▼
$42.44
Dividend Yield: N/A

44. AngioDynamics NASDAQ:ANGO

$9.37 +0.25 (+2.74%)

As of 03:16 PM Eastern

AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.

Market Capitalization: $379.29 million
P/E Ratio: -1.66
Consensus Rating: Buy
Consensus Price Target: $13.00 (+38.7% Upside)
Volume: 315,189 shares
Average Volume: 743,583 shares
Today's Range: $9.02
▼
$9.36
50-Day Range: $8.37
▼
$12.94
52-Week Range: $5.26
▼
$13.50
Dividend Yield: N/A

45. ClearPoint Neuro NASDAQ:CLPT

$13.06 +0.36 (+2.85%)

As of 03:16 PM Eastern

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

Market Capitalization: $361.70 million
P/E Ratio: -18.97
Consensus Rating: Buy
Consensus Price Target: $19.67 (+50.6% Upside)
Volume: 148,334 shares
Average Volume: 243,508 shares
Today's Range: $12.98
▼
$13.43
50-Day Range: $12.22
▼
$18.90
52-Week Range: $5.11
▼
$19.22
Dividend Yield: N/A

Remove Ads

46. NeuroPace NASDAQ:NPCE

$10.91 +0.55 (+5.35%)

As of 03:16 PM Eastern

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

Market Capitalization: $354.94 million
P/E Ratio: -10.90
Consensus Rating: Moderate Buy
Consensus Price Target: $15.20 (+39.3% Upside)
Volume: 95,437 shares
Average Volume: 121,478 shares
Today's Range: $10.24
▼
$11.00
50-Day Range: $10.04
▼
$14.69
52-Week Range: $5.45
▼
$15.77
Dividend Yield: N/A

47. Nyxoah NASDAQ:NYXH

$9.98 +0.03 (+0.30%)

As of 03:16 PM Eastern

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Market Capitalization: $339.89 million
P/E Ratio: -5.34
Consensus Rating: Buy
Consensus Price Target: $16.25 (+62.8% Upside)
Volume: 16,315 shares
Average Volume: 39,426 shares
Today's Range: $9.84
▼
$10.14
50-Day Range: $8.00
▼
$10.99
52-Week Range: $6.76
▼
$20.00
Dividend Yield: N/A

48. Tactile Systems Technology NASDAQ:TCMD

$13.34 -0.58 (-4.17%)

As of 03:16 PM Eastern

Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company also provides Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Tactile Systems Technology, Inc. was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.

Market Capitalization: $315.03 million
P/E Ratio: 19.08
Consensus Rating: Hold
Consensus Price Target: $18.00 (+34.9% Upside)
Volume: 392,080 shares
Average Volume: 248,202 shares
Today's Range: $13.22
▼
$14.16
50-Day Range: $13.77
▼
$17.99
52-Week Range: $11.12
▼
$21.10
Dividend Yield: N/A

49. CVRx NASDAQ:CVRX

$11.66 +0.10 (+0.87%)

As of 03:16 PM Eastern

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Market Capitalization: $303.71 million
P/E Ratio: -4.34
Consensus Rating: Moderate Buy
Consensus Price Target: $17.83 (+52.9% Upside)
Volume: 69,052 shares
Average Volume: 283,958 shares
Today's Range: $11.44
▼
$11.96
50-Day Range: $11.30
▼
$18.40
52-Week Range: $6.40
▼
$22.45
Dividend Yield: N/A

50. Pulmonx NASDAQ:LUNG

$7.31 +0.01 (+0.11%)

As of 03:16 PM Eastern

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Market Capitalization: $291.51 million
P/E Ratio: -5.09
Consensus Rating: Moderate Buy
Consensus Price Target: $13.36 (+82.8% Upside)
Volume: 90,440 shares
Average Volume: 334,635 shares
Today's Range: $7.07
▼
$7.65
50-Day Range: $5.68
▼
$9.20
52-Week Range: $5.46
▼
$10.01
Dividend Yield: N/A

Remove Ads

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Surgical & medical instruments Stocks List

Pros of Boston Scientific

Cons of Boston Scientific

Pros of Stryker

Cons of Stryker

Pros of Becton, Dickinson and Company

Cons of Becton, Dickinson and Company

Pros of ResMed

Cons of ResMed

Pros of DexCom

Cons of DexCom

Pros of Baxter International

Cons of Baxter International

Pros of West Pharmaceutical Services

Cons of West Pharmaceutical Services

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools